Magnesium oxide

ALIMENTARY TRACT AND METABOLISM

Key facts

Magnesium oxide is a drug catalogued in DrugCentral. It was first approved by the FDA in 1982. Recorded indications include Constipation, Hypocalcemia, Hypomagnesemia and Incomplete passage of stool.

• Indications: Constipation, Hypocalcemia, Hypomagnesemia, Incomplete passage of stool and Indigestion and others.
• ATC code: A02AA02 (Magnesium compounds).
• Molecular formula: MgO; molecular weight 40.30 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

• Constipation
• Hypocalcemia
• Hypomagnesemia
• Incomplete passage of stool
• Indigestion
• Osteoporosis
• Postmenopausal osteoporosis

Contraindications (39)

• Arteriosclerosis obliterans
• Bipolar disorder
• Blood coagulation disorder
• Carcinoma of female breast
• Chronic heart failure
• Conduction disorder of the heart
• Dehydration
• Diarrhea
• Disease of liver
• Endometrial carcinoma
• Esophageal Compression
• Esophageal dysmotility
• Gastrointestinal hemorrhage
• Gastrointestinal obstruction
• Gastroparesis
• Genitourinary Tract Infections
• Hypercalcemia
• Hypercalciuria
• Hyperkalemia
• Hyperparathyroidism
• Hyperphosphatemia
• Hypervitaminosis D
• Hypocupremia
• Hypomania
• Impaired renal function disorder
• Ketoacidosis in diabetes mellitus
• Kidney disease
• Kidney stone
• Low blood pressure
• Metabolic acidosis
• + 9 more

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1982-06-22	FDA	—	BAXTER HLTHCARE

ATC classification

ATC code	Therapeutic hierarchy
A02AA02	ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › ANTACIDS › Magnesium compounds
A06AD02	ALIMENTARY TRACT AND METABOLISM › DRUGS FOR CONSTIPATION › DRUGS FOR CONSTIPATION › Osmotically acting laxatives
A12CC10	ALIMENTARY TRACT AND METABOLISM › MINERAL SUPPLEMENTS › OTHER MINERAL SUPPLEMENTS › Magnesium

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Systemic lupus erythematosus	2231.0
Pemphigus	2216.9
Glossodynia	1928.0
Toxicity to various agents	1876.3
Hand deformity	1637.1
Arthropathy	1585.1
Completed suicide	1433.2
Alopecia	1431.7
Abdominal discomfort	1398.7
Wound	1316.7
Synovitis	1234.4
Maternal exposure during pregnancy	1223.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Magnesium oxide is on its molecule page.

• Molecular formula: MgO
• Molecular weight: 40.30 g/mol
• CAS number: 1309-48-4
• InChIKey: CPLXHLVBOLITMK-UHFFFAOYSA-N
• PubChem CID: 14792

O=[Mg]

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Magnesium oxide used for?

DrugCentral lists the following indications for Magnesium oxide: Constipation, Hypocalcemia, Hypomagnesemia, Incomplete passage of stool, Indigestion, Osteoporosis and Postmenopausal osteoporosis.

When was Magnesium oxide first approved?

Magnesium oxide was first approved by the FDA in 1982.

What is the chemical formula of Magnesium oxide?

Magnesium oxide has the molecular formula MgO and a molecular weight of 40.30 g/mol.

Sources

• DrugCentral drug card 4293 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200572 — compound record and bioactivity
• PubChem CID 14792 — chemical identifiers
• DrugBank DB01377 — drug record
• FDA UNII 3A3U0GI71G — substance identity
• DailyMed: FDA labels for Magnesium oxide — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.